[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644796":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":50,"collaborators":21,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":21,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":21,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Chongqing Peg-Bio Biopharm Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PL54","EXPERIMENTAL","subcutaneous injection administration. Single -dose escalation will start from the initial dose of 0.01 mg\u002Fkg and proceed sequentially to higher doses.",[13],"Biological: PL54",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Phase Ia:\n\nSingle, subcutaneous injection administration. Dose escalation will start from the initial dose of 0.01 mg\u002Fkg and proceed sequentially to higher doses.\n\nPhase Ib:\n\nAdministration via subcutaneous injection. Dosing frequency: once weekly. Dose escalation will start from the initial dose of 0.04 mg\u002Fkg and proceed sequentially to higher doses.",[9],[20],"PEGylated Recombinant Phenylalanine Ammonia-Lyase",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Jing Sun","CONTACT","86-13983367811","sunj@pegbiocq.com",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of Anhui Medical University","RECRUITING","Hefei","Anhui","230022","China","CN",{"type":38,"coordinates":39},"Point",[40,41],117.28083,31.86389,{"lat":41,"lon":40},[44,46,49],{"name":45,"role":25,"phone":26,"phoneExt":21,"email":27},"Huan Zhou",{"name":47,"role":48,"phone":21,"phoneExt":21,"email":21},"Jianping Weng","PRINCIPAL_INVESTIGATOR",{"name":45,"role":48,"phone":21,"phoneExt":21,"email":21},{"type":51,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100644796","phase-1-a-clinical-study-on-the-safety-and-tolerability-of-pl54-injection-in-adult-patients-with-phenylketonuria-pku-100644796",false,"NCT07672756","A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)","A Phase I Multicenter Open-label Dose-escalation Study of Safety, Tolerability, PK\u002FPD and Immunogenicity of Single\u002FMultiple Subcutaneous PL54 Injection in Adult PKU Patients","Key Inclusion Criteria:\n\n* Adult patients aged 18 to 55 years, inclusive, regardless of sex.\n* Subjects with a prior diagnosis of phenylketonuria (PKU) meeting the following criteria:\n\n  * Blood Phe concentration ≥600 µmol\u002FL at screening;\n  * Average blood Phe concentration ≥600 μmol\u002FL within the 12 months prior to screening (with at least two test results available);\n  * Genetic test report confirming the presence of phenylalanine hydroxylase (PAH) gene defects.\n* Ability to maintain dietary stability from 3 days prior to screening through the end of the trial.\n* Subjects (including partners) capable of practicing effective contraception during the trial period, with no plans for conception within 3 months after trial completion.\n* Voluntarily sign the informed consent form and, in the investigator's judgment, able to comply with all study requirements.\n\nKey Exclusion Criteria:\n\n* Known hypersensitivity to PL54 injection or any of its excipients.\n* Medical conditions or history assessed by the investigator that may increase the risk of severe allergic reactions (e.g., acute exacerbation of allergic asthma, atopic constitution, history of anaphylaxis, etc.).\n* Use of any medication for PKU (including large neutral amino acids) within 14 days prior to study drug administration or within 5 half-lives of the drug (whichever is longer).\n* Use or planned use of any injectable medication containing polyethylene glycol (PEG) (except the investigational drug) within 3 months prior to screening or during the study period, including medroxyprogesterone acetate injection.\n* Prior use of Pegvaliase (PALYNZIQ®).\n* History of any of the following manifestations associated with prior PEG-containing product use: systemic symptoms (e.g., respiratory or gastrointestinal symptoms, hypotension, angioedema, allergic reactions). The investigator will determine eligibility based on the severity of previous symptoms.\n* Clinically significant abnormal vital signs, physical examination, laboratory tests, or other relevant findings at screening, deemed by the investigator to render the subject unsuitable for enrollment.\n* Significant medical history of immunological, cardiovascular, respiratory, gastrointestinal, endocrine, renal, hematological, neurological, psychiatric, or malignant diseases (except basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been excised with no evidence of recurrence) assessed by the investigator prior to screening.\n* Stable use of immunosuppressants (e.g., cyclosporine, azathioprine) within 4 weeks prior to screening, with inability to discontinue use during the study period.\n* Vaccination within 4 weeks prior to screening or planned vaccination during the study period.\n* Positive serology for Treponema pallidum-specific antibodies, human immunodeficiency virus (HIV) antibodies, hepatitis C virus (HCV) antibodies, or hepatitis B virus (HBV) surface antigen.\n* Serum creatinine ratio \\> 1.5 × upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) \\> 2 × ULN.\n* Pregnant or breastfeeding women.\n* Participation in any investigational drug trial and receipt of an investigational product within 3 months prior to screening.\n* Prior use of any gene therapy for phenylketonuria (including participation in clinical studies).\n* Any other condition deemed by the investigator to preclude participation in the trial.","ALL","18 Years","55 Years",{"count":63,"type":64},48,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","The primary objective of this clinical trial is to evaluate the safety and tolerability of single and multiple administrations of PL54 in patients aged 18-55 years. The key questions it aims to answer include:\n\nHow safe and tolerable is PL54 in PKU patients following single and multiple administrations?\n\nResearchers will compare the safety and tolerability profiles between single and multiple dosing regimens to assess PL54.\n\nParticipants will be required to:\n\nPhase Ia (Single Administration):\n\nReceive a single subcutaneous injection of PL54 based on body weight. Undergo a 28-day observation period post-injection. Visit the clinic for assessments on: D1 (administration day), D2, D7, D8, D10, D15, D22, and D29.\n\nPhase Ib (Multiple Administrations):\n\nReceive subcutaneous injections of PL54 every 7 days (4 doses total) based on body weight. Undergo a 35-day observation period after the last injection. Visit the clinic for assessments on: D1 (first administration), D3, D8, D15, D21, D22, D29, D36, D43, and D57\n\nData to be recorded include:\n\nIncidence, severity, seriousness, relationship to PL54 treatment, duration, and outcome of adverse events (AEs).\n\nChange from baseline in blood phenylalanine (Phe) concentration.",[70],"Phenylketonuria (PKU)",[72,73],"Phenylketonuria","PKU","2026-06-28",{"date":76,"type":77},"2026-07-01","ACTUAL",{"date":79,"type":77},"2025-07-20",{"date":81,"type":64},"2027-08-01",{"name":5,"class":6},1]